My organization, Drugs for Neglected Diseases initiative (DNDi), first got involved with mycetoma after our team saw the way it impacts communities. First, the good news: In 2017, DNDi, working with the Mycetoma Research Center and Japanese pharmaceutical company Eisai, launched the world’s first randomized, double-blind clinical trial for mycetoma in Sudan. Finally, the disease’s inclusion on the WHO list of neglected diseases acted as a catalyst for global collaboration. The next 10 years of mycetoma care will determine whether it remains a story of neglect or becomes one of collective action. Borna Nyaoke-Anoke is a physician and the head of mycetoma disease at Drugs for Neglected Diseases initiative.